Ketamine Offers Hope to 1 in 3 Major Depression Patients, but 6 Sessions Cost About $2,400
Updated
Updated · WBAL TV Baltimore · May 11
Ketamine Offers Hope to 1 in 3 Major Depression Patients, but 6 Sessions Cost About $2,400
9 articles · Updated · WBAL TV Baltimore · May 11
About one-third of people with major depressive disorder do not respond to standard drugs or therapy, and clinics are increasingly using ketamine infusions or esketamine nasal spray to treat that group.
Ketamine works differently from antidepressants such as Prozac, targeting the NMDA receptor and glutamate to promote neuroplasticity and potentially speed healing when paired with psychotherapy.
At Maryland's Mood Center, patients typically receive six ketamine infusions over three weeks; each session costs about $400, while FDA-approved Spravato may be covered by insurance under strict rules.
James Soldinger, who said dozens of medications failed over years of severe depression, described relief after his first infusion, while his family said the treatment changed the course of their lives.
The treatment remains notable because ketamine is also known as a drug of abuse, yet clinicians say controlled medical use can be lifesaving for some of the 48 million U.S. adults living with depression.
Can science create a 'ketamine 2.0' that delivers relief without the intense psychedelic side effects?
As regulators crack down on ketamine clinics, will this mental health 'miracle' become a luxury for the wealthy?
If caffeine can block its effects, what other daily habits might undermine this breakthrough depression therapy?
Ketamine Therapy in Depression: Efficacy, Access Barriers, Patient Experience, and Future Directions
Overview
Ketamine is changing how severe depression is treated, offering rapid and strong antidepressant effects that can appear within hours and last for days after just one dose. This unique action has led to major research into its use and how it works in the brain. However, concerns about misuse mean that careful, evidence-based care is essential. Recent clinical trials, like the KARMA-Dep 2 study, are testing ketamine in real-world settings, showing both its promise and the challenges of ensuring safety and accurate results. As research continues, understanding ketamine’s benefits and risks is key to improving depression treatment.